Condition 1: Colon Cancer. Condition 2: Breast Cancer. Malignant neoplasm of colon Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Recubizol ointment (Nootech Pharm, Iran) will be applied to the surface of the hands and feet three times daily at a dose of 1 g per application (equivalent to two
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diagnosis of colon or breast cancer Candidate for chemotherapy with capecitabine at a dose of =1000 mg/m² Willingness and consent to participate in the study.
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding History of allergic or anaphylactic reactions to chamomile or calendula Use of pyridoxine or renin–angiotensin system inhibitors (captopril or enalapril). Skin conditions affecting the hands or feet that could confound outcome assessment; Presence of grade =2 neuropathy Concurrent and continuous use of oral or topical NSAIDs or aspirin Serious medical or psychiatric conditions that may limit the patient’s ability to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chemotherapy-induced hand-foot syndrome. Timepoint: Once weekly from week 1 to week 12 after initiation of chemotherapy. Method of measurement: Clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood cell counts and renal and hepatic indices. Timepoint: Once weekly from week 1 to week 12 after initiation of chemotherapy. Method of measurement: Complete blood cell count (CBC), serum urea, creatinine, and liver function tests including AST, ALT, ALP, and bilirubin. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Moradi
Hamedan University of Medical Sciences
Outcome results
None listed